Johnson & Johnson (JNJ) announced that the FDA granted full approval to its EFGR/MET inhibitor Rybrevant (amivantamab) in non-small cell lung cancer (NSCLC) indication.Following the FDA decision, Rybrevant, in combination with chemotherapy (carboplatin-pemetrexed), is approved for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The drug was initially granted accelerated approval for a similar indication in May 2021.Alongside the FDA appro ...

公司概况 - 强生公司是全球顶级医疗保健股之一，市值约为3900亿美元[1] - 过去十年，强生公司的股价上涨了76%，年复合增长率为5.8%，远低于标普500指数的长期平均水平[2] 业务发展 - 强生公司去年将其消费者健康业务剥离，以便更专注于增长机会，通过收购来增强前景[3] - 目前，强生公司有大约60个处于2期或3期试验阶段的项目，这有助于提高未来取得重大成功的机会[4] - 强生公司通过收购来加强长期前景，近年来一直在进行交易，如收购心脏泵制造商Abiomed和医疗器械公司Laminar[5] - 强生公司计划收购Ambrx Biopharma，这家公司生产抗体药物结合物，有助于靶向癌细胞以减少对健康细胞的风险[6] 未来展望 - 尽管进行了收购，但强生公司可能仍然无法成为高增长股，根据其长期指引，预计从2025年到2030年的年增长率在5%至7%之间[7] - 尽管预计创新药业务将拥有超过10个潜在销售额超过50亿美元的资产，但强生公司并不指望销售额会大幅增长[8] - 强生公司可能不会很快达到1万亿美元的估值，要实现这一目标，股价需要上涨156%[9] - 尽管强生公司未来可能无法成为高增长股，但股息投资者仍然可能看到该股的价值，因为其3%的股息和多年来惯例的年度增长[10]

Wall Street offers investors an assortment of pathways to make money. However, few strategies have been more successful over the long run than buying and holding dividend stocks.Last year, Hartford Funds released a report that thoroughly examined the ins and outs of dividend stocks over extended periods. In particular, a collaboration with Ned Davis Research found that income stocks averaged a 9.18% annual return over a half-century (1973-2022), with dividend growers and initiators really packing a punch (1 ...

As financial analysts know, no rule says large and long-lived companies need to be slowly growing investments. In that vein, Cantor Fitzgerald analyst Louise Chen on Feb. 20 reaffirmed her price target of $215 for Johnson & Johnson (JNJ 0.12%), suggesting that the stock could climb by as much as 33% from its current price near $161. Chen's estimate is an outlier, as the average price target of the financial analysts covering the stock is $175.But, in the context of the company being one of the world's bigge ...

Johnson & Johnson股价表现 - Johnson & Johnson (JNJ) 最新收盘价为$160.98，较前一天上涨了+0.12% [1] - 分析显示，Johnson & Johnson 过去一个月股价上涨了0.9%，但落后于医疗行业的5.86%和标普500指数的3.8% [2] Johnson & Johnson财务预测 - 预计 Johnson & Johnson 下一季度每股收益将为$2.64，较去年同期下降1.49%，营收预计为$21.38亿，较去年同期下降13.59% [3] - Zacks Consensus Estimates 预计 Johnson & Johnson 年度每股收益为$10.65，营收为$88.38亿，较去年分别增长了7.36%和下降了4.99% [4]

强生公司财务表现 - 强生公司报告的第四季度收入和调整后的每股收益略高于街头预期[1] - 强生公司股票表现波动较大，2021年收益率为9％，2022年为3％，2023年为-11％[2] - 公司预计2024年销售额将增长中等个位数，调整后的每股收益将在10.55美元至10.75美元之间[8] 强生公司业务表现 - 强生公司的创新药品和医疗技术业务收入分别增长4％和13％[5] - Darzalex和Stelara是公司近期的主要增长驱动因素[6]

Dividends are payments made by a corporation to its shareholders, usually derived from the company’s profits. Dividend stocks are those issued by companies that regularly distribute a portion of their earnings to shareholders. Investing in dividend stocks can be a strategy for generating regular income, in addition to potential stock price appreciation. These stocks are often associated with well-established, financially stable companies with a consistent track record of profitability.The advantages of inve ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ) . Shares have lost about 0.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Johnson & Johnson due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Beats Q4 Earnings & Sales Estimates ...

Johnson & Johnson (JNJ) closed at $158.68 in the latest trading session, marking a +0.52% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, lost 0.32%.The the stock of world's biggest maker of health care products has fallen by 1.22% in the past month, lagging the Medical sector's gain of 3.87% and the S&P 500's gain of 2.99%.Market participants will be closely following the financial results of Johnson & Johns ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this world's biggest maker of health care products have returned -1.2%, compared to the Zacks S&P 500 composite's +3% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Johnson & Johnson falls in, has gained 6.9%. The key question now ...